Associate Director/Lead International HTA Strategy - Oncology (all genders)

Allergan; Paris; Sur place; EUR 90 000 - 120 000; Plein temps

Résumé du poste

A global biopharmaceutical company is seeking an Associate Director / Lead in the International HTA Strategy team. The candidate will support the EU HTA process for new oncology assets and ensure that HTA evidence requirements are integrated early in the development process. This role involves implementing a robust HTA strategy, focused on achieving market access and enhancing patient access to innovative treatments.

Qualifications

• Strong understanding of market access strategies and HTA processes.
• Experience in evidence generation and support for successful P&R negotiations.
• Proven ability to work collaboratively within cross-functional teams.

Responsabilités

• Support the EU HTA process for new oncology assets.
• Ensure HTA evidence requirements are considered early in development.
• Implement a robust HTA strategy for successful asset launch.

Description du poste

Overview

Job Description

Advances in scientific and technological research are opening new, promising treatments for previously difficult to treat diseases, increasing the demand on already constrained healthcare budgets. The challenging economic and political environment is leading Health Technology Assessment (HTA) agencies and payers to demand better outcomes at lower cost to the overall health system. In 2021, the European Commission adopted the EU HTA regulation with the key objective of accelerating patient access to innovative treatments by harmonizing methodologies, establishing predictability and avoiding duplications. For AbbVie, this provides a unique opportunity to demonstrate the value attributes of our assets & strengthen affiliate position in country Pricing & Reimbursement (P&R) appraisals. Joint Clinical Assessment (JCA) is the key component of the EU HTA regulation and comprises the EU HTA dossier that will need to be submitted to the Member State Coordination Group on HTA, in which the evidence of relative effectiveness and relative safety is summarized within a single submission. For AbbVie, JCA will enable better planning of market access strategies across Europe, driving the perception of value, removing redundancies with repetitive dossiers, saving time and ultimately resulting in smoother P&R negotiations, aiming to achieve faster and broader access for patients.

To succeed in this environment, we (AbbVie) need to fully understand market value drivers, identify the evidence required for Pricing, Reimbursement and Access (PRA), and work with the evidence generating functions to ensure that evidence generated will support successful JCA and HTA outcome along with PRA negotiations.

The International HTA Strategy team was established to realize the full value of our assets by strategically informing drug development, evidence generation and HTA submissions, aligned with HTA / payer needs. The primary goals of the function are to ensure HTA evidence requirements are considered early in the development of AbbVie assets and implement a robust and aligned HTA strategy including EU HTA across the organization for the successful launch of Abbvie assets. The International HTA Strategy team oversees EU HTA Regulation implementation for AbbVie and leads Joint Scientific Consultation (JSC) and JCA strategy development and execution.

AbbVie is currently looking for an Associate Director / Lead within the International HTA Strategy team to support the EU HTA process for our new oncology assets